N/A N=31 Diagnostic

Investigation Into the Effects of Blood Glucose Levels Upon Eating Behavior in Lean and Obese Non-diabetic and Diabetic Subjects

Diabetes

Bottom Line

View on ClinicalTrials.gov: NCT02673203 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jan 2020

Primary outcome: Primary: Rate of Changing Glucose Level — 0.52; 0.44 mg/dl/min

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Continuous Glucose Monitoring System (CGMS) (Device); Food log (Behavioral)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Yale University
Primary completion: Dec 2017

Outcome Measures

Outcome	Result	p-value
PRIMARY Rate of Changing Glucose Level	0.52; 0.44	—
PRIMARY Glucose Peak	119.5; 121.5	—
PRIMARY Glucose Nadir	85.1; 87.1	—
SECONDARY Difference in Glucose Peak and Nadir	34.3; 33.9	—
SECONDARY Average Daily Hunger Rating	5.8; 5.6	—
SECONDARY Nutirion Intake: Energy	2251.5; 2167.8	—
SECONDARY Nutirion Intake: Carbohydrate	261.1; 251.8	—
SECONDARY Nutirion Intake: Fat	92.4; 97.5	—
SECONDARY Nutirion Intake: Protein	99.9; 80.9	—

Summary

To investigate whether the daily glucose profiles as assessed by continuous glucose monitoring for 1 week of normal weight and obese individuals relate to hunger levels and food intake.

Eligibility Criteria

Inclusion Criteria

A1c 1.5 mg/dL,
Hgb 2.5 X ULN,
untreated thyroid disease,
uncontrolled hypertension,
known neurological disorders,
untreated psychiatric disorders,
use of antidepressants and psychiatric medications,
use of weight loss medications in the 6 months prior to the study,
malignancy,
smoking,
current or recent steroid use in last 3 months,
history of current illicit drug use;
for women: pregnancy, or breastfeeding.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02673203). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.